Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma
- 7 May 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (19), 1685-1695
- https://doi.org/10.1182/blood.2019003880
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell acute lymphoblastic lymphoma (T-LBL) are aggressive hematological malignancies that are currently treated with highdose chemotherapy. Over the last several years, the search toward novel and less-toxic therapeutic strategies for T-ALL/T-LBL patients has largely focused on the identification of cell-intrinsic properties of the tumor cell. However, non-cell-autonomous activation of specific oncogenic pathways might also offer opportunities that could be exploited at the therapeutic level. In line with this, we here show that endogenous interleukin 7 (IL7) can increase the expression of the oncogenic kinase proviral integration site for Moloneymurine leukemia 1 (PIM1) in CD1271 T-ALL/T-LBL, thereby rendering these tumor cells sensitive to in vivo PIM inhibition. In addition, using different CD1271 T-ALL/T-LBL xenograft models, we also reveal that residual tumor cells, which remain present after shortterm in vivo chemotherapy, display consistent upregulation of PIM1 as compared with bulk nontreated tumor cells. Notably, this effect was transient as increased PIM1 levels were not observed in reestablished disease after abrogation of the initial chemotherapy. Furthermore, we uncover that this phenomenon is, at least in part, mediated by the ability of glucocorticoids to cause transcriptional upregulation of IL7RA in T-ALL/T-LBL patient-derived xenograft (PDX) cells, ultimately resulting in non-cell-autonomous PIM1 upregulation by endogenous IL7. Finally, we confirm in vivo that chemotherapy in combination with a pan-PIM inhibitor can improve leukemia survival in a PDX model of CD1271 T-ALL. Altogether, our work reveals that IL7 and glucocorticoids coordinately drive aberrant activation of PIM1 and suggests that IL7-responsive CD1271 T-ALL and T-LBL patients could benefit from PIM inhibition during induction chemotherapy.This publication has 47 references indexed in Scilit:
- For better or for worse: the role of Pim oncogenes in tumorigenesisNature Reviews Cancer, 2010
- Glucocorticoid use in acute lymphoblastic leukaemiaThe Lancet Oncology, 2010
- Pim-1 Kinase Protects P-Glycoprotein from Degradation and Enables Its Glycosylation and Cell Surface ExpressionMolecular Pharmacology, 2010
- A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphomaBlood, 2010
- Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migrationThe Journal of Experimental Medicine, 2009
- Molecular‐genetic insights in paediatric T‐cell acute lymphoblastic leukaemiaBritish Journal of Haematology, 2008
- Pim Kinases Promote Cell Cycle Progression by Phosphorylating and Down-regulating p27Kip1 at the Transcriptional and Posttranscriptional LevelsCancer Research, 2008
- Pim kinase-dependent inhibition of c-Myc degradationOncogene, 2008
- Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper siteFEBS Letters, 2004
- Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal regionCell, 1984